ClinicalTrials.gg

Program

soquelitinib

Also written as “Soquelitinib” and “CPI-818”.

Its studies are mostly in Lymphoma, T-Cell · Dermatitis, Atopic · Hidradenitis Suppurativa, led by Corvus Pharmaceuticals.

Furthest: phase 3, since Aug 16, 20245 company-led studies, 4 open or runningNext primary completion: Dec 30, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Corvus Pharmaceuticals54 open or runningphase 3since Aug 16, 2024May 7, 2019Dec 30, 2026phase 1 · NCT03952078

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 7, 2019First study: phase 1 study in Lymphoma, T-CellFirst studyNCT03952078 · 151 enrolled · United States, Australia, China and more
  2. Mar 12, 2024Phase 1 study in Dermatitis, AtopicNCT06345404 · 82 enrolled · United States
  3. Aug 16, 2024Phase 3 study in Lymphoma, T-CellNCT06561048 · 150 planned · United States, Australia, Canada
  4. Feb 23, 2026Phase 2 study in Dermatitis, AtopicNCT07441395 · 200 planned · United States
  5. Sep 3, 2026Phase 1 study in Hidradenitis SuppurativaNCT07828860 · 25 planned · United States

Ahead

  1. Dec 30, 2026Primary completion: phase 1 study in Lymphoma, T-CellNCT03952078
  2. Jun 2027Primary completion: phase 2 study in Dermatitis, AtopicNCT07441395
  3. Nov 2027Primary completion: phase 3 study in Lymphoma, T-CellNCT06561048
  4. Dec 2027Primary completion: phase 1 study in Hidradenitis SuppurativaNCT07828860

TargetBeta

ITK →read by rule
“An orally available, small-molecule, irreversible inhibitor of interleukin-2 inducible T-cell kinase (ITK) ”NCIt, by rule

Other programs on ITK

ProgramCompanyFurthest phaseStudies
ritlecitinibrulePfizerphase 342

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07828860Hidradenitis Suppurativa · United States1RecruitingDec 202725
NCT07441395Dermatitis, Atopic · United States2RecruitingJun 2027200
NCT06561048Lymphoma, T-Cell · United States, Australia, Canada3RecruitingNov 2027150
NCT06345404Dermatitis, Atopic · United States1CompletedJan 28, 202682
NCT03952078Lymphoma, T-Cell · United States, Australia, China and more1Active, not recruitingDec 30, 2026151

How it is read

Names in the registry

  • “Soquelitinib”, 4 entries
  • “CPI-818”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.